Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Germany flag Germany · Delayed Price · Currency is EUR
616.20
+4.00 (0.65%)
Last updated: Dec 5, 2025, 8:10 AM CET
-13.21%
Market Cap 63.59B
Revenue (ttm) 12.14B
Net Income (ttm) 3.90B
Shares Out n/a
EPS (ttm) 35.45
PE Ratio 16.30
Forward PE 15.70
Dividend 3.14 (0.51%)
Ex-Dividend Date Nov 20, 2025
Volume n/a
Average Volume 49
Open 616.20
Previous Close 612.20
Day's Range 616.20 - 616.20
52-Week Range 420.00 - 752.00
Beta n/a
RSI 52.02
Earnings Date Feb 3, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,106
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RGO
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD Financial Statements

News

There is no news available yet.